Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge

Mattia Bellan(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mario Pirisi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
JAMA Network Open
January 27, 2021
10.1001/jamanetworkopen.2020.36142
Cited by 493

Related Papers

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
|The Lancet|2021|315
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
|Hepatology|2024|52
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
|JAMA Oncology|2024|37